111786-07-3
基本信息
Prinoxodan
Prinoxodan (RGW2938)
2(1H)-Quinazolinone, 3,4-dihydro-3-methyl-6-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-
物理化学性质
熔点 | >250 °C |
密度 | 1.47±0.1 g/cm3(Predicted) |
储存条件 | -20°C储存 |
溶解度 | 溶于二甲基亚砜 |
酸度系数(pKa) | 13.58±0.40(Predicted) |
形态 | Solid |
颜色 | White to yellow |
安全数据
危险性符号(GHS) | GHS07 |
警示词 | 警告 |
危险性描述 | H302-H315-H319-H335 |
防范说明 | P261-P305+P351+P338 |
常见问题列表
Phosphodiesterase
Prinoxodan (RG W-2938) is an orally effective positive inotropic/vasodilator agent. Prinoxodan is a new nonglycoside, noncatecholamine cardiotonic/vasodilator agent is examined in vitro in isolated guinea pig hearts; in the latter, Prinoxodan 5 nmol-5 μmol increases contractility in a dose-related fashion.
Prinoxodan (RG W-2938) is a new nonglycoside, noncatecholamine cardiotonic/vasodilator agent is examined in vivo in anesthetized and conscious dogs. Prinoxodan 30-300 μg/kg administered intravenously (i.v.) to anesthetized dogs increases contractile force while decreasing arterial pressure and total peripheral resistance (TPR) in a dose-related manner. Heart rate (HR) is only slightly increased, and aortic flow is not appreciably altered. A single oral dose of Prinoxodan 0.3 mg/kg administered to conscious chronically instrumented dogs produces a marked and sustained increase in contractility 15-240 min after treatment while only slightly increasing HR. The effects of Prinoxodan 30-300 μg/kg, i.v. are studied in a mecamylamine-propranolol-induced model of heart failure. Prinoxodan effectively reverses the drug-induced heart failure by increasing myocardial contractility and decreasing arterial pressure while only slightly affecting HR.